Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00038805
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Not Applicable
Terminated
- Conditions
- Non Hodgkin's LymphomaAplastic AnemiaLeukemia
- Interventions
- Procedure: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00038779
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
- First Posted Date
- 2002-06-05
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00038701
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Not Applicable
Completed
- Conditions
- Chronic Myelomonocytic LeukemiaHypereosinophilic SyndromePolycythemia VeraMastocytosisChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2002-06-05
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 125
- Registration Number
- NCT00038675
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
Phase 2
Completed
- Conditions
- Myelogenous Leukemia, Chronic
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00038597
- Locations
- 🇺🇸
MDAnderson Cancer Center, Houston, Texas, United States
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 117
- Registration Number
- NCT00038649
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00038610
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Drug: Yttrium-ibritumomab (Zevalin)
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00038623
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00038545
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
Phase 1
Completed
- Conditions
- Cancer of Head and NeckCarcinoma, Squamous Cell
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00038584
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath